Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vonderfecht, S. L.
Right arrow Articles by Ware, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vonderfecht, S. L.
Right arrow Articles by Ware, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 32, No. 3, 318-325 (2004)
DOI: 10.1080/01926230490431763

Myopathy Related to Administration of a Cationic Amphiphilic Drug and the Use of Multidose Drug Distribution Analysis to Predict its Occurrence

Steven L. Vonderfecht

Worldwide Safety Sciences Pfizer Inc., Kalamazoo, Michigan 49007, USA, vonderfechtsl{at}lilly.com

Marjorie L. Stone

Worldwide Safety Sciences Pfizer Inc., Kalamazoo, Michigan 49007, USA

Robert R. Eversole

Biological Imaging Center, Department of Biological Sciences, Western Michigan University, Kalamazoo, Michigan 49008, USA

Mark F. Yancey

Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Kalamazoo, Michigan 49007, USA

Margaret R. Schuette

Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Kalamazoo, Michigan 49007, USA

Barbara A. Duncan

Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Kalamazoo, Michigan 49007, USA

Joseph A. Ware

Pharmacokinetics, Dynamics and Drug Metabolism, Pfizer Global Research and Development, Pfizer Inc., Kalamazoo, Michigan 49007, USA

Many cationic amphiphilic (phospholipidosis-inducing) drugs (CADs) accumulate in tissues following repeated dosing in preclinical models, and this is sometimes associated with dose-limiting toxicities. Plasma drug levels cannot be used to estimate tissue accumulation of CADs since it occurs in tissues despite stabilization of plasma levels. Severe myopathy was found in skeletal muscles of rats during the initial safety evaluation of a dopamine D3 receptor antagonist, PNU-177864, and was associated with phospholipidosis in numerous tissues. The myopathy was observed only when plasma levels of PNU-177864 remained essentially constant throughout the 24-hour dosing period. A repeat dose drug distribution study using whole body autoradiography demonstrated that drug-related material did not accumulate in skeletal muscle or other tissues following repeated doses at levels considered within the therapeutic range and showing toxicokinetic profiles acceptable for further development. These observations provided support for the continued development of and longer-term toxicity studies with this candidate compound.

Key Words: Skeletal muscle • pathology • myopathy • phospholipidosis • phospholipid • rats • autoradiography.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
D. G. Rudmann, M. E. Mcnerney, S. L. Vandereide, J. K. Schemmer, R. R. Eversole, and S. L. Vonderfecht
Epididymal and Systemic Phospholipidosis in Rats and Dogs Treated with the Dopamine D3 Selective Antagonist PNU-177864
Toxicol Pathol, April 1, 2004; 32(3): 326 - 332.
[Abstract] [PDF]